Brought to you by 
EyeGate buys Jade Therapeutics for $2.57mm in stock, plus earnouts
08 Sep 2020
Executive Summary
EyeGate Pharmaceuticals Inc. acquired privately held ophthalmic firm Jade Therapeutics Inc. for $2.57mm in stock (EyeGate issued about 766k common shares) and will repay Jade liabilities of up to $300k. The deal also includes a $2.16mm potential earn-out payment should one of Jade's products receive FDA approval.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
-
Medical Devices
- Biomaterials
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
EyeGate buys Jade Therapeutics for $2.57mm in stock, plus earnouts
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice